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Background and objective: Non-compartmental analysis (NCA) calculates pharmacokinetic
(PK)  metrics related to the systemic exposure to a drug following administration, e.g. area
under the concentration–time curve and peak concentration. We  developed a new package
in  R, called ncappc,  to perform (i) a NCA and (ii) simulation-based posterior predictive checks
(ppc)  for a population PK (PopPK) model using NCA metrics.
Methods: The nca feature of ncappc package estimates the NCA metrics by NCA. The ppc fea-
ture  of ncappc estimates the NCA metrics from multiple sets of simulated concentration–time
data  and compares them with those estimated from the observed data. The diagnostic
analysis is performed at the population as well as the individual level. The distribution
of  the simulated population means of each NCA metric is compared with the correspond-
ing  observed population mean. The individual level comparison is performed based on the
deviation of the mean of any NCA metric based on simulations for an individual from the
corresponding NCA metric obtained from the observed data. The ncappc package also reports
the  normalized prediction distribution error (NPDE) of the simulated NCA metrics for each
individual and their distribution within a population.
Results: The ncappc produces two default outputs depending on the type of analysis per-
formed, i.e., NCA and PopPK diagnosis. The PopPK diagnosis feature of ncappc produces
8  sets of graphical outputs to assess the ability of a population model to simulate the
concentration–time proﬁle of a drug and thereby evaluate model adequacy. In addition,
tabular outputs are generated showing the values of the NCA metrics estimated from the
observed and the simulated data, along with the deviation, NPDE, regression parameters
used  to estimate the elimination rate constant and the related population statistics.
Conclusions: The ncappc package is a versatile and ﬂexible tool-set written in R that success-
fully estimates NCA metrics from concentration–time data and produces a comprehensive
set of graphical and tabular output to summarize the diagnostic results including the modelspeciﬁc outliers. The out
tion  PK model. ncappc is 
ncappc/index.html/) and 
©  2016 The Authors. Publ
the  CC BY-NC
∗ Corresponding author. Tel.: +46 18 471 4304.
E-mail address: chayan.acharya@farmbio.uu.se (C. Acharya).
ttp://dx.doi.org/10.1016/j.cmpb.2016.01.013
169-2607/© 2016 The Authors. Published by Elsevier Ireland Ltd. T
http://creativecommons.org/licenses/by-nc-nd/4.0/).put is easy to interpret and to use in evaluation of a popula-
freely available on CRAN (http://cran.r-project.org/web/packages/
GitHub (https://github.com/cacha0227/ncappc/).
ished by Elsevier Ireland Ltd. This is an open access article under
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
his is an open access article under the CC BY-NC-ND license
m s i n84  c o m p u t e r m e t h o d s a n d p r o g r a 
1.  Introduction
The principal objective of the pharmacokinetics (PK) stud-
ies is to understand the kinetics of a drug molecule in
terms of absorption, distribution, metabolism and elimina-
tion (ADME). PK data analysis can primarily be classiﬁed
into non-compartmental analysis (NCA) and model-based
analysis, where the latter can range from compartment mod-
els to physiology-based models [1]. The NCA beneﬁts from
fewer assumptions, compared to model-based approaches. In
NCA, the area under the curve (AUC), peak observed drug
concentration (Cmax), time of peak concentration (Tmax), ter-
minal elimination rate constant (Lambda z), terminal half-life
(HL Lambda z) and other metrics are estimated to determine
the systemic exposure of a drug following administration. NCA
is typically an essential part of PK analysis in the ﬁeld of drug
discovery and in richly sampled clinical PK studies. Regulatory
decisions regarding bioequivalence studies are often based
on comparisons of AUC and Cmax, in particular. Additionally,
NCA may also be used as a diagnostic tool to evaluate the
performance of any compartmental population pharmacoki-
netic (PopPK) models by comparing the NCA metrics obtained
from simulated concentration–time data to the same metrics
obtained from the observed concentration–time proﬁle. This
can provide information on the models ability to provide ade-
quate description of exposure measures that are typically
judged as important for richly sampled concentration–time
proﬁles.
A number of software tools (such as Kinetica [2], WinNonlin
[3], PK module in R [4], Scientist [5], PKSolver [6]) are available
that can perform NCA. As a novelty, we have extended the use
of NCA as a pharmacometric model diagnostic tool employing
the principles of a posterior predictive check [7] with the NCA
metrics as test statistics. In this article we report a simulation-
based diagnostic package, called ncappc,  written in R [8] that
(i) provides a simple and ﬂexible method to estimate the NCA
metrics from the observed data and (ii) compares them with
the same metric estimated from multiple data sets simulated
using the PopPK model to be diagnosed. Thus ncappc helps to
bridge the gap between NCA and population model analyses.
ncappc package can potentially facilitate the early stage of the
drug discovery process by evaluating the performance of the
related PopPK model and identify the model speciﬁc outliers.
2.  Methods
2.1.  Implementation  and  the  usage  of  the  ncappc
package
The ncappc package is implemented in R and accepts a set of
input arguments, resulting in certain processing of data and
output production. Table 1 depicts the list of acceptable argu-
ments with default values of the arguments. The names of
most of the NCA metrics estimated by the ncappc function are
consistent with those used in WinNonlin [3]. A comparison of
NCA metrics obtained by the ncappc package and WinNonlin
showed no discrepancies and the results can be found in the
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obsFile and simFile arguments, used in ncappc,  represent
the observed and the simulated data. The default values
of these two arguments are “nca original.npctab.dta” and
“nca simulation.1.npctab.dta”, respectively. To perform NCA,
obsFile argument should be adjusted to the correct name of the
observed data ﬁle. If simFile argument is NULL and the working
directory does not contain “nca simulation.1.npctab.dta”, only
nca feature of this package will be executed. The name of the
simulation output ﬁle, structured as is common in table ﬁles
of many  software including NONMEM [9] is supplied via simFile
argument to use the ppc feature of the package. All other argu-
ments are optional and their default value may be adjusted
according to the description given in Table 1.
There are three arguments (namely str1Nm, str2Nm and
str3Nm) in ncappc that can be used to stratify the study popula-
tion. For a single layer of stratiﬁcation any of these arguments
can be used. If they are used in combination, the population is
stratiﬁed into nested layers, where str1Nm, str2Nm and str3Nm
represent the 1st, 2nd and 3rd levels of stratiﬁcation, respec-
tively.
If no units are supplied for the dose, time or concentration,
ncappc labels the NCA metrics with appropriate dimension-
ality in terms of mass (M), length (L) and time (T). Fig. 1
displays the workﬂow of this function. If the simFile argument
is omitted only NCA on observed data is performed while
inclusion of the simFile argument results in both NCA calcu-
lations and the ppc-based diagnostics. Details of the output
generated by ncappc package are described in the Supplemen-
tary material-II. In brief, the NCA feature produces two sets
of ﬁgures displaying the concentration vs. time proﬁle for
each individual within a certain population group and the his-
togram of four NCA metrics (AUClast, AUCINF obs, Cmax and
Tmax) estimated from the observed data (see the Supplemen-
tary material-I for the deﬁnitions). Additionally, two  tables are
produced representing the estimated individual values of the
NCA metrics obtained from the observed data and the values
of various population statistics of each of the NCA metrics
estimated from the observed data, respectively. Please see the
Supplementary material-II for the description of the output
tables and ﬁgures generated by ncappc.
In the presence of the simulated data obtained using of
the concerned PopPK model, ncappc function estimates the
same set of NCA metrics from each set of the simulations.
Next, the function performs the individual and population
level diagnostic tests and produces a complete report with
the graphical and tabular outputs reporting the individual and
population level diagnostic results involving simulation mean,
deviation from the observed value and Normalized Prediction
Distribution Error (NPDE) values of each NCA metric. All tables
produced by ncappc are in tab-separated text format and can be
easily loaded in generic data visualization software like Excel,
R, etc.
2.2.  Simulation-based  PopPK  model  evaluation  in
ncappc  packageThe objective of this feature of the ncappc package is to perform
a PopPK model evaluation using simulation-based diagnostics
by comparing the NCA metrics estimated from the simulated
data with the same metrics estimated from the observed data.
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Table 1 – Description and expected values of the ncappc arguments.
Name  Description Example of possible values Default
obsFile Observed concentration–time data from an internal data frame
or an external table with comma, tab or space as separator
File name or data frame “nca original.npctab.dta”
simFile Simulated concentration–time data in NONMEM format from
an internal data frame or an external table
File  name or data frame “nca simulation.1.npctab.dta”
str1Nm Column name for 1st level population stratiﬁer Column name NULL
str1 Stratiﬁcation ID of the members within 1st level stratiﬁcation c(1,2) NULL
str2Nm Column name for 2nd level population stratiﬁer Column name NULL
str2 Stratiﬁcation ID of the members within 2nd level stratiﬁcation c(1,2) NULL
str3Nm Column name for 3rd level population stratiﬁer Column name NULL
str3 Stratiﬁcation ID of the members within 3rd level stratiﬁcation c(1,2) NULL
concUnit Unit of the concentration “ng/mL” “M.L-ˆ3”
timeUnit Unit of the time “h” “T”
doseUnit Unit of the dose “g” “M”
doseNormUnit Normalization factor for dose “kg” NULL
obsLog Concentration in observed data in logarithmic Logical (TRUE or FALSE) FALSE
simLog Concentration in simulated data in logarithmic Logical (TRUE or FALSE) FALSE
psnOut Observed data is an output from PsN (in NONMEM output
format)
Logical (TRUE or FALSE) FALSE
idNmObs Column name for ID in observed data Column name “ID”
timeNmObs Column name for time in observed data Column name “TIME”
concNmObs Column name for concentration in observed data Column name “DV”
idNmSim Column name for ID in simulated data Column name “ID”
timeNmSim Column name for time in simulated data Column name “TIME”
concNmSim Column name for concentration in simulated data Column name “DV”
AUCTimeRange Range of time to compute AUC Lower and upper limit of time (e.g.
c(0,24))
NULL
backExtrp Option to back extrapolate to predict initial concentration C0 Logical (TRUE or FALSE) FALSE
LambdaTimeRange Range of time to compute Lambda z Lower and upper limit of time (e.g.
c(15,24))
NULL
LambdaExclude Time points to be excluded from Lambda z calculation Numeric (e.g. c(20,24)) NULL
doseAmtNm Column name for dose amount Column name AMT
adminType Dose administration type “iv-bolus”, “iv-infusion”,
“extravascular”
“extravascular”
doseType Steady state or non-steady state of dose “ns” or “ss” “ns”
doseTime Dose time prior to the ﬁrst observation for steady-state data Numeric NULL
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Table 1 – (Continued)
Name  Description Example of possible values Default
Tau Steady state dosing interval Numeric NULL
TI Infusion duration Numeric NULL
method Computational method to estimate AUC and AUMC “linear”, “log”, “linear-log” “linear-log”
blqNm Column name for BLQ data Column name NULL
blqExcl BLQ column values to be excluded Numeric or logical (e.g. 1, c(1,2),
“>=1”)
1
evid Use EVID column to ﬁlter data Logical (TRUE or FALSE) TRUE
evidIncl EVID values to be included Numeric (e.g. 0) 0
mdv Use MDV column to ﬁlter data Logical (TRUE or FALSE) FALSE
ﬁlterNm Column name to ﬁlter data Column name NULL
ﬁlterExcl Filter identiﬁers used to exclude data Numeric or logical condition (e.g.
1, c(1,2), “>=1”)
NULL
negConcExcl Exclude negative concentrations Logical (TRUE or FALSE) FALSE
param NCA metrics used for diagnostics c(“AUClast”, “AUClower upper”,
“AUCINF obs”, “AUCINF pred”,
“AUMClast”, “Cmax”, “Tmax”,
“HL Lambda z”)
c(“AUClast”, “Cmax”)
timeFormat Data format for time Number, H:M, H:M:S “number”
dateColNm Name of the date column Column name for date NULL
dateFormat Format of the date D-M-Y, M-D-Y, Y-M-D, D/M/Y,
M/D/Y, Y/M/D
NULL
spread Measure of the spread of simulated data “ppi” (95% parametric prediction
interval) or “npi” (95%
nonparametric prediction interval)
“npi”
tabCol Output columns to be printed in the report in addition to ID,
dose and population strata information
List  of NCA metrics in a string
array
c(“AUClast”, “Cmax”, “Tmax”,
“AUCINF obs”, “Vz obs”,
“Cl obs”, “HL Lambda z”)
ﬁgFormat Format of the produced ﬁgures (“bmp”, “jpeg”, “tiff”, “png”) “tiff”
noPlot Suppression of plot generation Logical (TRUE or FALSE) FALSE
printOut Write/print output on the disk Logical (TRUE or FALSE) TRUE
studyName Name of the study to be added as a description in the report Study description NULL
new data method For testing a faster method of reading data Logical (TRUE or FALSE) TRUE
overwrite SIMDATA Create new information in the SIMDATA directory, or to use the
information in the SIMDATA
TRUE,  FALSE or NULL NULL
outFileNm Additional tag to the name of the output html and pdf output
ﬁle hyphenated to the standard ncappc report ﬁle name
Output ﬁle name tag Name of the observed data ﬁle
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Fig. 1 – Workﬂow of ncappc package displaying two different logical paths of the package based on the availability of the
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pimulation output data set. See Supplementary material-II f
s NONMEM [9] is the most widely used software in non-linear
ixed-effect modeling of PK/PD data, currently the model
valuation part of the ncappc package is based on the sim-
lation output obtained from NONMEM, but other software
an generate the same type of output to be used as input
or this routine. The PopPK model to be evaluated is used to
imulate k sets of the plasma concentration vs. time proﬁle
sing NONMEM, where k is a positive integer. ncappc produces
 sets of NCA metrics for each individual from the simulated
ata. This package allows the user to employ any combination
f the following eight NCA metrics for the model evaluation
ests: AUClast, AUClower upper, AUCINF obs, AUCINF pred,
UMClast, Cmax, Tmax, HL Lambda z (see the Supplemen-
ary material-I for the deﬁnitions). As a defult, ncappc uses
UClast and Cmax for model evaluation tests. The NCA metrics
btained from the observed and the simulated data are sub-
ected to the following set of diagnostic tests to evaluate the
erformance of the PopPK model.
.2.1.  Population  level  diagnostics
.2.1.1.  Comparison  of  the  population  means.  A complete set
f NCA metrics are estimated for each individual from each
et of simulated data. The population mean of each of the NCA
etrics is calculated for every single set of the simulated data.
he probability distribution of the population means of each
CA metric estimated from the simulated data is compared
raphically with the population mean of the corresponding
CA metric estimated from the observed data. In the presence
f stratiﬁed population, the population means are calculated
or each stratum separately for the comparison. Depending on
he value of the spread argument to the function, the spread
f the simulated distribution can be quantiﬁed as: (i) 95%
arametric prediction interval (ppi) or (ii) 95% nonparametrictailed description of tables and ﬁgures generated.
prediction interval (npi). For derivation of prediction inter-
vals, see Supplementary material-I. As a preliminary graphical
analysis, this function detects if the NCA metric estimated
from the observed data lies within 95% ppi or npi of the dis-
tribution of the population mean of the NCA metric estimated
from the simulated data.
2.2.1.2.  Population  NPDEs  of  NCA  metrics.  Based on the simu-
lated data sets the NPDE of the NCA metrics for each individual
is computed using the method reported by Comets et al. [10].
The population mean and SD (including imprecision) of the
NPDEs are compared with the expected values (i.e. mean 0,
SD 1) in forest plots. The probability density of the NPDE val-
ues for the entire population is produced and compared with
respect to the normal distribution with mean 0 and variance 1.
2.2.2.  Individual  level  diagnostics
2.2.2.1.  Deviation  from  the  observed  data  and  identiﬁcation  of
outliers.  As a part of the individual level diagnosis, deviation
of the simulation-based mean of the NCA metrics for each
individual from the corresponding NCA metrics estimated
from the observed data are calculated by subtracting the
individual simulation-based mean of the NCA metrics from
the same estimated from the observed data. The value of
the deviation is scaled by the spread of the corresponding
simulated distribution (measured either as 95% ppi or 95%
npi). In case of ppi, the deviation is divided by the distance of
the simulation mean to the 95% ppi boundary; in case of 95%
npi, the deviation is divided by the distance of the simulation
mean to the 95% npi boundary nearer to the observed value.
Such deviation is calculated for each of the NCA metrics used
for model diagnosis. A negative value of the deviation signiﬁes
over-prediction of the corresponding NCA metric, while a
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Table 2 – Data summary of Moxonidine PK study.
Group ID (DGRP)a Occasion ID
(VISI)a
Daily dose
(g)a
No. of
individualsa
No. of
outliersb
Selected outliers
ID and NCA
metricsb
7 3 200 24 0
7 8 200 21 2 ID402-Cmax, ID802-AUClast
8 3 200 26 0
8 8 400 25 2 ID606-AUClast, ID906-AUClast
9 3 200 24 1 ID322-AUClast, ID322-Cmax
9 8 600 24 0
a Obtained from the input data.
b Obtained from the results of ncappc.positive value of the deviation signiﬁes under-prediction of
the same. An individual yielding the absolute value of the
scaled deviation >1, corresponding to the individual lying
outside of the corresponding 95% prediction interval of the
model, for any of the NCA metrics used for model diagnosis is
considered as an outlier for the speciﬁc model. For an outlier
the probability distribution of the NCA metric compared with
the corresponding observed values are reported graphically.
2.2.2.2.  Individual  NPDE  of  NCA  metrics.  The NPDE values
for the NCA metrics for each individual are calculated and
reported. Theoretically the NPDE values should be distributed
normally with a mean of 0 and SD of 1. The distribution of the
individual NPDE values for each NCA metric is plotted for each
population stratum to detect any trend or model bias.
Fig. 2 – Concentration vs. time proﬁle of the individuals in DGRP
panels represent the raw data, while the right panels represent t
the lines represents individual data.3.  Results
3.1.  Case  study  with  Moxonidine
Moxonidine is a centrally acting antihypertensive drug used
for the treatment of mild to moderate hypertension. Here we
present a case study to illustrate the package of ncappc package
using the data obtained from the population pharmacokinetic
study reported by Karlsson et al. [11]. The basic information
regarding the Moxonidine PK data set is shown in Table 2. In
this study 74 patients were included in the active treatment
group and treated with extravascular dose of Moxonidine.
Patients receiving the active treatment were divided into three
population groups or treatment arms (DGRP 7, 8 and 9) and
each arm received Moxonidine in two different occasions (VISI
 7 and VISI 3 obtained form the observed data. The left
he semi-logarithmic form of the concentration data. Each of
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Fig. 3 – Population histogram of four selected NCA metrics (AUClast, AUCINF obs, Cmax, Tmax) estimated from the observed
data for DGRP 7 for VISI 3. The solid and dashed blue vertical lines represent the population mean and the spread of the
observed data. The spread is deﬁned by 2.5th and 97.5th percentile boundaries of the NCA metrics obtained from the
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Nbserved data.
 and 8). The individuals in DGRP 7 received 200 g of daily dose
or both occasions (VISI 3 and VISI 8); the individuals in DGRP
 received 200 g daily dose at the ﬁrst occasion (VISI 3) and
hen 400 g daily dose at the second occasion (VISI 8) and the
ndividuals in DGRP 9 received 200 g daily dose and 600 g
aily dose of Moxonidine in VISI 3 and VISI 8, respectively.
harmacokinetic sampling was performed at both occasions
or each subject. A one-compartmental linear PopPK model
ith ﬁrst-order absorption with lagtime was used to simulate
he concentration vs. time proﬁle 1000 times for each indi-
idual. The NCA metrics were estimated from both observed
nd simulated data sets. AUClast and Cmax metrics were used
or the diagnostic tests. Fig. 2 presents the plasma concen-
ration proﬁle of the individuals obtained from the observed
ata. Fig. 3 represents the population distribution of four NCA
etrics (AUClast, AUCINF obs, Cmax and Tmax) estimated from
he observed data. The solid and dashed blue vertical lines rep-
esent the population mean and the spread of the NCA metrics
stimated from the observed data. The spread is deﬁned by
he 2.5th and 97.5th percentile boundaries of the NCA metrics
btained from the observed data..1.1.  Comparison  of  population  means  (population  level
nalysis)
ig. 4 represents the histogram of the population mean of the
CA metrics estimated from the set of simulated data. Thespread of the distribution of the simulated NCA metrics was
measured by the 95% npi, calculated from the distribution of
the population means estimated from each set of simulated
data.
3.1.1.1.  Evaluation  of  report.  The graphical report of the dis-
tribution of the estimated population means compared to the
observed population of the NCA metrics is used to determine
the general performance of the PopPK model to reproduce
the drug exposure proﬁle for the entire population. In gen-
eral, if the 95% npi of the distribution of the simulated NCA
metrics used for the diagnostics fail to encompass the pop-
ulation mean of the corresponding NCA metrics estimated
from the observed data, the PopPK model may be revisited for
improvement. In this case, the given PopPK model is able to
satisfy the condition with respect to AUClast and Cmax.
3.1.2.  Deviation  of  simulated  mean  from  observed  value
(individual  level  analysis)
Fig. 5 represents the deviation of the mean of each of the two
NCA metrics for each individual within DGRP 7 and VISI 3 esti-
mated from the 1000 sets of simulated data from the value
of the same metric estimated from the observed data. The
raw values of the deviations were scaled by dividing them by
the distance between the simulation mean and the 95% npi
boundary nearer to the observed value.
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Fig. 4 – Histogram of the population mean of the AUClast and Cmax obtained from the simulated data from the simulations
for the individuals in DGRP 7 for VISI 3. The red and blue solid vertical lines represent the population mean of the NCA
metric obtained from the observed data (mean(obs)) and the mean of the population means of the same NCA metric
obtained from the simulations (mean(meanSim)), respectively. The blue dashed vertical lines represent the spread or 95%
nonparametric prediction interval boundaries for the population mean of the NCA metrics obtained from the simulated data.3.1.2.1.  Evaluation  of  report.  The values of the scaled devia-
tion for each individual within a speciﬁc treatment arm or
population group are used to detect model misspeciﬁcation
and individual outliers. Any individual yielding the absolute
Fig. 5 – Deviation of the mean of the NCA metrics for each indivi
data obtained from the simulations (meanSim) from the correspo
deviation is scaled by the spread of the simulated data, which is,
the PK simulated metric value and the 95% nonparametric predi
proximal to the observed value (Deviation = (Obs meanSim)/dista
prediction interval boundary nearer to the Obs).value of the scaled deviation greater than 1 is labeled as an
outlier by ncappc for the PopPK model. The total number of
identiﬁed outliers in the case of Moxonidine data set was
5 out of 74 individuals and across 2 different metrics
dual in DGRP 7 and VISI 3 estimated from the simulated
nding values estimated from the observed data (Obs). The
 in this case, deﬁned by the distance between the mean of
ction interval boundary of the simulated metric distribution
nce between meanSim and the 95% nonparametric
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Fig. 6 – The individual 402 in DGRP 7 for VISI 8 is identiﬁed as an in this example for the corresponding PopPK model. This
individual is labeled as outlier as the value of the Cmax obtained from the observed data is outside the 95% npi of the
distribution of the Cmax values obtained from the simulated data set. The red and blue solid vertical lines represent the
observed metric value and the mean of the simulated metric values for that individual, respectively. The dashed blue
vertical lines represent the 95% npi for the distribution of the simulated metric values.
(
i
m
t
F
a
h
dCmax and AUClast) and 2 proﬁles per subject. Last column
n Table 2 lists the ID numbers and the corresponding NCA
etric of the individuals who  are assigned as outliers for
heir corresponding population groups under the given PopPK
ig. 7 – Forest plot displaying the population mean and standard
nd dose groups. The red and green dots represent the mean and
orizontal lines represent the corresponding 95% conﬁdence inte
eviation along with the corresponding 95% conﬁdence intervalsmodel. Fig. 6 illustrate the probability distribution of the NCA
metrics of one of these outliers (ID-402 DGRP-7 VISI-8) where
the absolute value of the scaled deviation of Cmax was greater
than 1.
 deviation of the NPDE values stratiﬁed on treatment arms
 the standard deviation of the NPDE, respectively while the
rvals. The values of the population mean and standard
 are shown in the ﬁgure.
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Fig. 8 – NPDE type analysis for each individual in DGRP 7 and VISI 3. NPDE values were  calculated from the corresponding
observed and simulated values of the NCA metrics. The negative value of the NPDE signiﬁes over-prediction of the
corresponding NCA metrics, while a positive value of the NPDE signiﬁes under-prediction of the same.3.1.3.  NPDE  of  NCA  metrics  (both  population  and
individual  level  analysis)
The NPDE values of all NCA metrics used in diagnostics for
each individual are reported. The population mean and the
standard deviation of the NPDE values for the NCA metrics
are also calculated and shown in a forest plot (Fig. 7) along
with the corresponding 95% conﬁdence intervals. For deriva-
tion of conﬁdence intervals, see Supplementary material-I.
Fig. 9 – Histogram of the NPDE values of all individuals for the N
represents the mean of the ideal NPDE or normal distribution (m
mean of the estimated NPDE distribution for the corresponding p
standard deviation of the distribution of the NPDE.Fig. 8 represents the NPDE values of AUClast and Cmax for each
individual in DGRP 7 and VISI 3. Fig. 9 represents the probabil-
ity distribution of the NPDE values for all individuals within a
speciﬁc treatment arm and occasion group DGRP 7 and VISI 3.3.1.3.1.  Evaluation  of  report.  The forest plot (Fig. 6) shows
that the mean NPDE values of AUClast and Cmax of all treat-
ment arms and occasions. For an acceptable PopPK model, the
CA metrics in DGRP 7 and VISI 3. The red solid vertical
ean = 0, SD = 1). The blue solid vertical lines represent the
opulation. The dashed blue vertical lines represent the
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opulation mean and SD along with their conﬁdence inter-
al should encompass 0 and 1, respectively. The population
odel successfully produces the 95% conﬁdence intervals of
he mean of the NPDE values encompassing 0, however, the
5% conﬁdence intervals of the SD of the NPDEs of AUClast in
GRP 8 for VISI 3 and the same of Cmax in DGRP 8 for VISI 8
ail to encompass 1. This indicates a discrepancy between the
opPK model and the observed data for these metrics in these
reatment groups. Nonetheless, Figs. 8 and 9 do not show any
ystematic trend of errors for AUClast and Cmax.
The results of the above mentioned set of population level
nd individual level diagnostic tests for the studied PopPK
odel are systematically reported by the ncappc package and
t produces a complete report in HTML and PDF format. The
esults of the diagnostic tests can be used to identify model
isspeciﬁcations at the population level; the results of the
cappc can also be used to identify speciﬁc individuals, which
re misﬁts to the concerned PopPK model or to the deﬁni-
ion of the population strata. The conclusions drawn based
n the diagnostics will be dependent on the intended use of
he model and also which speciﬁc model aspect that this diag-
ostic is used for. Thus, the consequence of the diagnostics for
he further model development will vary between project and
riteria. An acceptable discrepancy may need to be deﬁned for
ach case. For example, if the main purpose of the model is
o describe the general tendency in the data, the population
evel diagnostics will be of most importance.
.  Conclusion
he ncappc package is a versatile and ﬂexible tool-set written in
 that successfully estimates the NCA metrics related to NCA
rom the observed and a set of simulated concentration–time
ata. It produces a comprehensive set of graphical and tab-
lar output to summarize the results of the diagnostic tests
ncluding the model speciﬁc outliers. The output is easy to
nterpret and to use in evaluation of a population model. This
rogram also produces a complete report in PDF and HTML
ormat. ncappc is freely available on CRAN and GitHub at the
ollowing URL, respectively.
CRAN: http://cran.r-project.org/web/packages/ncappc/
ndex.html/.
GitHub: https://github.com/cacha0227/ncappc/.
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Appendix  A.  Supplementary  data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.cmpb.
2016.01.013.
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